N-tert-butyl-4-ethylbenzamide | 162330-15-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-tert-butyl-4-ethylbenzamide
• CAS: 162330-15-6
• 化学式: C₁₃H₁₉NO
• mdl: MFCD08816475
• 分子量: 205.3
• InChiKey: XNGGZFBGSHJLTE-UHFFFAOYSA-N

物化性质

• 熔点：
  121-123 °C
• 沸点：
  333.9±21.0 °C(Predicted)
• 密度：
  0.967±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.461
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-tert-butyl-4-ethylbenzamide 在 N-溴代丁二酰亚胺(NBS) 、 过氧化苯甲酰 作用下， 以 四氯化碳 为溶剂， 以83%的产率得到(+/-)-4-(1-bromoethyl)-N-tert-butylbenzamide
  参考文献：
  名称：

  Novel 5α-reductase inhibitors. Synthesis and structure-activity studies of 5-substituted 1-methyl-2-pyridones and 1-methyl-2-piperidones

  摘要：

  In search for nonsteroidal inhibitors of 5 alpha-reductase for the treatment of benign prostatic hyperplasia (BPH) and possibly prostate cancer, substrate mimicks were synthesized comprising of a 1-methyl-2-pyridone (2, 4-16) or 1-methyl-2-piperidone (1, 3, 17-22) moiety (mimicking steroidal ring A) and a diisopropyl (1, 2, (E)-5-(E)-7, (Z)-5-(Z)-7, 11-13, 17-19) or a tert-butyl (3, 4, (E)-8-(E)-10, (Z)-8(Z)-10, 14-16, 20-22) benzamide (mimicking steroidal ring D). The bridge connecting the 5 and 4 positions of the rings consisted of amide (CONH: 1-4), ethenyl (CH=CH, CCH3=CH, CH=CH3: (E)-5-(E)-10, (Z)-5(Z)-10) or ethylene groups (CH2CH2, CHCH3CH2, CH2CHCH3: 11-22). The amides 1-4 were obtained by amidation of the carboxylic acid chlorides with the 4-amino-N-substituted benzamides. The ethenyl compounds (E)-5(E)-10 and (Z)-5-(Z)-10 were synthesized by Wittig reaction of the carbonyl compounds and the corresponding triphenylphosphonium salts and subsequent separation of the stereoisomers. Depending on the time of reaction, catalytic hydrogenation of the ethenyl isomers (E)-5-(E)-10 led to the pyridone-substituted ethylene compounds 11-16 as well as to the piperidone-substituted ethylene compounds 17-22. The 5 alpha-reductase inhibitory properties were determined using rat ventral prostate, as well as human BPH and prostate cancer as source, 1 beta,2 beta-[H-3]testosterone as substrate and a HPLC procedure for the separation of dihydrotestosterone (DHT). Tested at a concentration of 100 mu M, the inhibition values of 1-22 ranged from 0-99%. Significant differences were observed between rat and human enzyme. The most active compound was N,N-diisopropyl-4-[2-(1-methyl-2-oxo-piperidine-5-yl)ethylene]benzamide 17 (IC50: 13 mu M).

  DOI：

  10.1016/0223-5234(94)90104-x
• 作为产物：
  描述：

  4-Ethyl-benzoic acid N-tert-butyl-hydrazide 在 sodium hydroxide 、 sodium hydride 作用下， 以 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 12.0h， 生成 N-tert-butyl-4-ethylbenzamide
  参考文献：
  名称：

  <i>N</i>'-<i>tert</i>-Butyl-<i>N</i>'-aroyl-<i>N</i>-(alko×ycarbonylmethyl)-<i>N</i>-aroylhydrazines, a novel nonsteroidal ecdysone agonist: syntheses, insecticidal activity, conformational, and crystal structure analysis

  摘要：

  Seventeen N'-tert-butyl-N'-aroyl-N-(alkoxycarbonylmethyl)-N-aroylhydrazines were synthesized, and their insecticidal activities against armyworm (Leucania separata (Walker)) were tested. The conformation and structure of compound 1b was studied by H-1 NMR spectroscopy and X-ray crystallography. The crystal structure belongs to the orthorhombic system and the N-N bond adopts a gauche conformation, which was assumed to be the active conformation, with a dihedral angle of 69.9 degrees.

  DOI：

  10.1139/cjc-79-3-272

文献信息

• Synthesis of Amides via Palladium-Catalyzed Amidation of Aryl Halides
  作者：Huanfeng Jiang、Bifu Liu、Yibiao Li、Azhong Wang、Huawen Huang

  DOI：10.1021/ol103081y

  日期：2011.3.4

  A new and efficient method for the synthesis of amides via palladium-catalyzed C−C coupling of aryl halides with isocyanides is reported, by which a series of amides were formed from readily available starting materials under mild conditions. This transformation could extend its use to the synthesis of natural products and significant pharmaceuticals.

  报道了通过钯催化的芳基卤化物与异氰酸酯的C-C偶联合成酰胺的一种新的有效方法，通过该方法在温和的条件下由易于获得的起始原料形成了一系列酰胺。这种转变可以将其用途扩展到天然产物和重要药物的合成。
• Palladium/Copper-Catalyzed Oxidative Coupling of Arylboronic Acids with Isocyanides: Selective Routes to Amides and Diaryl Ketones
  作者：Fangling Lu、Ziyue Chen、Zhen Li、Xiaoyan Wang、Xinyue Peng、Cong Li、Lingtong Fang、Dong Liu、Meng Gao、Aiwen Lei

  DOI：10.1021/acs.orglett.7b01548

  日期：2017.8.4

  An efficient and alternative oxidative cross-coupling strategy starting from arylboronic acids and isocyanides for the selective synthesis of amides and diaryl ketones with palladium/copper catalysis is developed. Various substituted benzamides and benzophenones could be obtained in good yields. The reaction represents an efficient and alternative strategy for the synthesis of carbonyl compounds.

  从钯/铜催化选择性合成酰胺和二芳基酮开始，开发了一种从芳基硼酸和异氰化物开始的有效且交替的氧化交叉偶联策略。可以高产率获得各种取代的苯甲酰胺和二苯甲酮。该反应代表了羰基化合物合成的有效和替代策略。
• ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS
  申请人：Parker F. Michael

  公开号：US20080085894A1

  公开（公告）日：2008-04-10

  There is provided a series of novel α-(N-sulfonamido)acetamide compounds of the Formula (I) wherein R, R 1 , R 2 and R 3 are defined herein, which are inhibitors of β-amyloid peptide (β-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions affected by anti-amyloid activity.

  提供了一系列新型α-(N-磺酰胺基)乙酰胺化合物的公式(I)，其中R、R1、R2和R3在此定义，它们是β-淀粉样肽（β-AP）产生的抑制剂，并且在治疗阿尔茨海默病和其他受到抗淀粉样蛋白活性影响的疾病中有用。
• ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL
  申请人：Gambacorti Passerini Carlo

  公开号：US20110281862A1

  公开（公告）日：2011-11-17

  The present invention relates to compounds of formula (I) wherein R1, R2 and R3 are as defined in the description, to their pharmaceutical compositions and use thereof for the treatment of cancer expressing oncogenic ALK protein, particularly anaplastic large cell lymphoma (ALCL), diffuse large B cell lymphoma (DLBCL), inflammatory myofibroblastic tumours (IMT) and non-small cell lung cancer (NSCLC).

  本发明涉及式（I）的化合物，其中R1，R2和R3如描述中所定义，以及它们的制药组合物和用于治疗表达癌基因ALK蛋白的癌症的用途，特别是间变性大细胞淋巴瘤（ALCL），弥漫性大B细胞淋巴瘤（DLBCL），炎性肌成纤维细胞瘤（IMT）和非小细胞肺癌（NSCLC）。
• Carboxamide, Sulfonamide and Amine Compounds and Methods for Using Them
  申请人：Rigel Pharmaceuticals, Inc.

  公开号：US20140378429A1

  公开（公告）日：2014-12-25

  The disclosure relates particularly to certain carboxamide, sulfonamide and amine compounds and pharmaceutical compositions thereof, and to methods of treating and ameliorating disorders and conditions related to the adiponectin pathway, sphingolipid metabolism, oxidative stress, mitochondrial dysfunction, free radical damage and metabolic inefficiency, among others. In certain embodiments, the compounds have the structures (I-1), (2-I) and (3-I) (The chemical formulas should be inserted here) in which the variables are as described herein.

  本公开涉及特定的羧酰胺、磺酰胺和胺化合物及其制药组合物，以及治疗和改善与脂联素途径、鞘脂代谢、氧化应激、线粒体功能障碍、自由基损伤和代谢效率等相关的疾病和病症的方法。在某些实施例中，化合物具有结构（I-1）、（2-I）和（3-I）（化学式应在此处插入），其中变量如本文所述。